Zeitschrift für Rheumatologie

, Volume 73, Issue 8, pp 742–745 | Cite as

Mean platelet volume in patients with fibromyalgia

  • S. Haliloğlu
  • A. Carlioglu
  • E. Sahiner
  • Y. Karaaslan
  • A. Kosar
Originalien

Abstract

Fibromyalgia is a syndrome characterised by chronic widespread pain at multiple tender points, as well as joint stiffness and systemic symptoms. The aetiology and pathogenesis of fibromyalgia still remain unclear, although many contributory factors have been suggested. The presence of some common features between fibromyalgia and cardiovascular risk factors (e.g. depression and sleep disturbance) led to question of whether there is there a relationship between fibromyalgia and cardiovascular disease and/or atherosclerosis. Mean platelet volume, which is a determinant of platelet activation, is a newly emerging independent risk factor for cardiovascular disease.

The present study was designed to evaluate levels of mean platelet volume in patients with fibromyalgia; the study population consisted of 283 individuals with this syndrome, who were compared with 72 healthy controls. Erythrocyte sedimentation rate, C-reactive protein, white blood cell count, platelet count and mean platelet volume levels were retrospectively recorded via the computerised patient database. The levels of mean platelet volume were significantly higher in the fibromyalgia group than in the control group (8.09 ± 0.84 fl and 7.73 ± 0.65 fl, respectively, p < 0.001). There were no statistical differences between groups with regard to platelet count and other parameters. These results suggest that an early atherosclerosis marker, mean platelet volume, is elevated in patients with fibromyalgia. This indicates increased platelet activation and therefore a higher risk of future cardiovascular disease.

Keywords

Fibromyalgia Mean platelet volume Cardiovascular diseases Risk factors Platelet activation 

Mittleres Thrombozytenvolumen bei Patienten mit Fibromyalgie

Zusammenfassung

Fibromyalgie ist ein Syndrom, das durch chronische, an mehreren Tenderpoints verbreitete Schmerzen sowie durch Gelenksteife und systemische Symptome gekennzeichnet ist. Ätiologie und Pathogenese der Fibromyalgie sind immer noch ungeklärt, auch wenn viele mitwirkende Faktoren genannt worden sind. Das Vorliegen einiger gemeinsamer Merkmale von Fibromyalgie und kardiovaskulären Risikofaktoren (z. B. Depression und Schlafstörungen) führte zu der Frage, ob es einen Zusammenhang zwischen Fibromyalgie und Herz-Kreislauf-Erkrankungen und/oder Atherosklerose gebe. Das mittlere Thrombozytenvolumen, ein Parameter der Thromobozytenaktivierung, ist ein neu aufkommender unabhängiger Risikofaktor für Herz-Kreislauf-Erkrankungen.

Mit der vorliegenden Studie sollte die Höhe des mittleren Thrombozytenvolumens bei Patienten mit Fibromyalgie ermittelt werden; die Studienpopulation bestand aus 283 Personen mit diesem Syndrom, welche mit 72 gesunden Kontrollen verglichen wurden. Blutsenkungsgeschwindigkeit, C-reaktives Protein, Leukozytenzahl, Thrombozytenzahl und mittleres Thrombozytenvolumen wurden retrospektiv anhand der elektronischen Patientendatenbank erfasst. Die Werte für das mittlere Thrombozytenvolumen waren in der Gruppe mit Fibromyalgie signifikant höher als in der Kontrollgruppe (8,09 ± 0,84 fl bzw. 7,73 ± 0,65 fl; p < 0,001). Es gab keine statistischen Unterschiede zwischen den Gruppen in Hinblick auf die Thrombozytenzahl und andere Parameter. Diese Ergebnisse sprechen dafür, dass ein früher Atherosklerosemarker, das mittlere Thrombozytenvolumen, bei Patienten mit Fibromyalgie erhöht ist. Das ist ein Anzeichen einer erhöhten Thrombozytenaktivierung und somit eines höheren Risikos zukünftiger Herz-Kreislauf-Erkrankungen.

Schlüsselwörter

Fibromyalgie Mittleres Thrombozytenvolumen Kardiovaskuläre Erkrankungen Risikofaktoren Plättchenaktivierung 

References

  1. 1.
    Bigatti SM, Hernandez AM, Cronan TA, Rand KL (2008) Sleep disturbances infibromyalgia syndrome: relationship to pain and depression. Arthritis Care Res 59(7):961–967CrossRefGoogle Scholar
  2. 2.
    Clauw DJ (2009) Fibromyalgia: an overview. Am J Med 122(12):3–13CrossRefGoogle Scholar
  3. 3.
    Bellato E, Marini E, Castoldi F et al (2012) Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat. doi:10.1155/2012/426130Google Scholar
  4. 4.
    Smith HS, Harris R, Clauw D (2011) Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 14(2):217–245Google Scholar
  5. 5.
    Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172PubMedCrossRefGoogle Scholar
  6. 6.
    Wolfe F (2010) New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res 62(5):583–584CrossRefGoogle Scholar
  7. 7.
    Wolfe F, Clauw DJ, Fitzcharles MA et al (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62(5):600–610CrossRefGoogle Scholar
  8. 8.
    Assumpção A, Cavalcante AB, Capela CE et al (2009) Prevalence of fibromyalgia in a low socioeconomic status population. BMC Musculoskelet Disord 10:64PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Branco JC, Bannwarth B, Failde I et al (2010) Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 39(6):448–453PubMedCrossRefGoogle Scholar
  10. 10.
    Rozanski A (2005) Integrating psychologic approaches into the behavioral management of cardiac patients. Psychosom Med 67(Suppl 1):S67–S73PubMedCrossRefGoogle Scholar
  11. 11.
    Miller MA (2011) Association of inflammatory markers with cardiovascular risk and sleepiness. J Clin Sleep Med 7(5 Suppl):S31–S33PubMedPubMedCentralGoogle Scholar
  12. 12.
    Yılmaz H, Ertugrul O, Ertugrul B, Ertugrul D (2011) Mean platelet volume in patients with subclinical hypothyroidism. Platelets 22(2):143–147PubMedCrossRefGoogle Scholar
  13. 13.
    Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG (2011) High platelet volume and increased risk of myocardial infarction: 39531 participants from the general population. J Thromb Haemost 9:49–56PubMedCrossRefGoogle Scholar
  14. 14.
    Kosus N, Kosus A, Turhan NO (2011) Relationship of ovarian volume with mean platelet volume and lipid profile in patients with polycystic ovary syndrome. Exp Ther Med 2:1141–1144PubMedPubMedCentralGoogle Scholar
  15. 15.
    Martin JF, Trowbridge EA, Salmon G, Plumb J (1983) The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1:443–460CrossRefGoogle Scholar
  16. 16.
    Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 17:47–58PubMedCrossRefGoogle Scholar
  17. 17.
    Bavbek N, Kargili A, Kaftan O et al (2007) Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy? Clin Appl Thromb Hemost 13:391–397PubMedCrossRefGoogle Scholar
  18. 18.
    Makay B, Turkyilmaz Z, Unsal E (2009) Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 28:975–978PubMedCrossRefGoogle Scholar
  19. 19.
    Thompson CB (1986) From precursor to product: how do megakaryocytes produce platelets? Prog Clin Biol Res 215:361–371PubMedGoogle Scholar
  20. 20.
    Thompson CB, Jakubowski JA (1988) The pathophysiology and clinical relevance of platelet heterogeneity. Blood 72:1–8PubMedGoogle Scholar
  21. 21.
    Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339–3347PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Miyazaki H, Kato T (1999) Thrombopoietin: biology and clinical potentials. Int J Hematol 70:216–225PubMedGoogle Scholar
  23. 23.
    Butkiewicz AM, Kemona-Chetnik I, Dymicka-Piekarska V et al (2006) Does smoking affect thrombocytopoiesis and platelet activation in women and men? Adv Med Sci 51:123–126PubMedGoogle Scholar
  24. 24.
    Tavil Y, Sen N, Yazici HU et al (2007) Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 120:245–250PubMedCrossRefGoogle Scholar
  25. 25.
    Mitchell MD, Mannino DM, Steinke DT et al (2011) Association of smoking and chronic pain syndromes in Kentucky women. J Pain 12(8):892–899PubMedCrossRefGoogle Scholar
  26. 26.
    Cordero MD, Alcocer-Gómez E, Cano-García FJ et al (2013) Clinical symptoms in fibromyalgia are associated to overweight and lipid profile. Rheumatol Int. doi:10.1007/s00296-012-2647-2Google Scholar
  27. 27.
    Arranz L, Angel Canela M, Rafecas M (2012) Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients. Rheumatol Int 32:3605–3611PubMedCrossRefGoogle Scholar
  28. 28.
    Jahan F, Nanji K, Qidwai W, Qasim R (2012) Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. Oman Med J 27:192–195PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Thompson CB, Eaton KA, Princiotta SM et al (1982) Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 50:509–519PubMedCrossRefGoogle Scholar
  30. 30.
    Vizioli L, Muscari S, Muscari A (2009) The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 63:1509–1515PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • S. Haliloğlu
    • 1
  • A. Carlioglu
    • 2
  • E. Sahiner
    • 3
  • Y. Karaaslan
    • 4
  • A. Kosar
    • 5
  1. 1.Department of Physical Medicine and RehabilitationErzurum Regional Research and Training HospitalErzurumTurkey
  2. 2.Department of EndocrinologyErzurum Regional Research and Training HospitalErzurumTurkey
  3. 3.Department of Internal Medicine, Faculty of MedicineFatih UniversityAnkaraTurkey
  4. 4.Department of RheumatologyAnkara Numune Research and Training HospitalAnkaraTurkey
  5. 5.Department of Hematology, Faculty of MedicineFatih UniversityAnkaraTurkey

Personalised recommendations